Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Delcath Systems Inc (DCTH)

Delcath Systems Inc (DCTH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 223,121
  • Shares Outstanding, K 27,786
  • Annual Sales, $ 2,070 K
  • Annual Income, $ -47,680 K
  • 60-Month Beta 0.55
  • Price/Sales 101.86
  • Price/Cash Flow N/A
  • Price/Book 13.23
Trade DCTH with:

Options Overview Details

View History
  • Implied Volatility 72.15% ( -3.04%)
  • Historical Volatility 96.32%
  • IV Percentile 14%
  • IV Rank 17.49%
  • IV High 380.22% on 08/14/23
  • IV Low 6.84% on 07/24/23
  • Put/Call Vol Ratio 0.13
  • Today's Volume 404
  • Volume Avg (30-Day) 336
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 4,564
  • Open Int (30-Day) 6,111

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.34
  • Number of Estimates 1
  • High Estimate -0.34
  • Low Estimate -0.34
  • Prior Year -0.58
  • Growth Rate Est. (year over year) +41.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.87 +66.12%
on 04/22/24
8.50 -4.82%
on 05/21/24
+3.22 (+66.12%)
since 04/19/24
3-Month
3.70 +118.65%
on 03/14/24
8.50 -4.82%
on 05/21/24
+3.88 (+92.16%)
since 02/21/24
52-Week
2.25 +259.56%
on 11/14/23
8.50 -4.82%
on 05/21/24
+1.01 (+14.27%)
since 05/19/23

Most Recent Stories

More News
Delcath Systems Announces a Comparative Study of Chemosat and SIRT Published in the Journal Cancers

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

DCTH : 8.09 (+0.75%)
Delcath Systems to Participate in the Lytham Partners Fall 2023 Investor Conference

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

DCTH : 8.09 (+0.75%)
Delcath Systems to Participate at the Roth MKM 2023 Healthcare Opportunities Conference on October 12, 2023

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

DCTH : 8.09 (+0.75%)
Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and...

DCTH : 8.09 (+0.75%)
A Retrospective Comparative Study of Chemosat and SIRT Presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Meeting

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

DCTH : 8.09 (+0.75%)
Delcath Systems to Participate at the H.C. Wainwright 25th Annual Investor Conference on September 12 and 13, 2023

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

DCTH : 8.09 (+0.75%)
Delcath Systems, Inc. Announces Additional $35 Million in Funding Tied to the FDA Approval of HEPZATO KIT™

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

DCTH : 8.09 (+0.75%)
Stock Index Futures Plunge on Pressure from Rising Bond Yields, China Data Disappoints

September S&P 500 futures (ESU23) are down -0.61%, and September Nasdaq 100 E-Mini futures (NQU23) are down -0.48% this morning as market participants digested the latest U.K. employment data, which fueled...

ESU23 : 4,491.72s (-0.32%)
NQU23 : 15,435.20s (-0.28%)
NVDA : 953.86 (+0.64%)
X : 36.16 (-1.61%)
MNDY : 241.45 (+5.25%)
TSLA : 186.60 (+6.66%)
KEY : 15.32 (+0.59%)
CMA : 53.60 (+0.28%)
HD : 336.15 (-0.49%)
SU : 41.05 (+3.01%)
ALC : 88.70 (+0.68%)
A : 153.67 (-0.63%)
Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT™ for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

DCTH : 8.09 (+0.75%)
Delcath Systems Reports Second Quarter 2023 Results and Provides Business Update

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and...

DCTH : 8.09 (+0.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Delcath Systems, Inc. has developed a system, the Delcath system, to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver.

See More

Key Turning Points

3rd Resistance Point 9.11
2nd Resistance Point 8.80
1st Resistance Point 8.45
Last Price 8.09
1st Support Level 7.79
2nd Support Level 7.48
3rd Support Level 7.13

See More

52-Week High 8.50
Last Price 8.09
Fibonacci 61.8% 6.11
Fibonacci 50% 5.38
Fibonacci 38.2% 4.64
52-Week Low 2.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar